FDA
label_change
· 2014-10-17
FDA Approved: COMBIVENT RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
The FDA approved a supplemental application for Combivent Respimat to update the product labeling. Combivent Respimat is a combination inhaler containing ipratr…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for COMBIVENT RESPIMAT (IPRATROPIUM BROMIDE AND ALBUTEROL)